DNA vaccine aims to train immune system against lung cancer
NCT ID NCT05242965
First seen Apr 14, 2026 · Last updated Jun 23, 2026 · Updated 9 times
Summary
This phase II trial tests a DNA vaccine called STEMVAC in 5 people with stage IV non-small cell lung cancer. The vaccine gives the body instructions to make parts of five proteins found on lung cancer cells, with the goal of activating immune cells to attack the tumor. Participants receive the vaccine along with an immune booster (GM-CSF) while on standard maintenance therapy. The study looks at safety and whether the vaccine can shrink tumors.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LUNG NON-SMALL CELL CARCINOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Fred Hutch/University of Washington Cancer Consortium
Seattle, Washington, 98109, United States
-
University of Nebraska Medical Center
Omaha, Nebraska, 98198, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
STEMVAC (a DNA vaccine targeting five cancer proteins) given with GM-CSF (an immune booster)
What this could lead to
If it works, this could point toward a new way to help the immune system recognize and attack lung cancer cells, potentially slowing tumor growth.
What could go wrong
This is a very small, early-phase trial with only 5 participants, so results may not apply broadly. The vaccine may not produce a strong enough immune response or shrink tumors, and side effects are possible.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.